RxDoctor Payments Data

Mark Saleh, MD

Neurology · Palo Alto, CANPI 1851352264

Payments from drug & device makers

$21,561in general payments, 2019–2025

Across 652 payments — averaging $33.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$8K
  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$951
  • Biogen$904
  • Neurocrine Biosciences, Inc.$746
  • Pfizer$681
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$6003%
  • Speaking & faculty fees$6,26729%
  • Travel & lodging$1,1605%
  • Food & beverage$13,05561%
  • Education$4802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,561 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$368,815
Medicare patients
396
Services billed
33,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate59$76,821
GocovriAmantadine Hcl14$69,410
BriviactBrivaracetam25$48,812
QuliptaAtogepant32$39,564
NourianzIstradefylline19$35,362
XcopriCenobamate23$26,444
UbrelvyUbrogepant18$24,690
RytaryCarbidopa/Levodopa14$14,925
Rasagiline Mesylate61$14,486
Carbidopa-LevodopaCarbidopa/Levodopa329$12,890
Sumatriptan Succinate82$9,327
EliquisApixaban11$6,213
Entacapone14$5,650
Gabapentin192$5,452
Carbamazepine ErCarbamazepine20$4,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$681$83,03470 claims
MDD US Operations, LLCGocovri$535$69,41014 claims
AbbVieQulipta, Ubrelvy$3,251$64,25550 claims
UCB, Inc.Briviact$632$48,81225 claims
Kyowa Kirin, Inc.Nourianz$85$35,36219 claims
SK Life Science, Inc.Xcopri$8,446$26,44423 claims
Amneal Pharmaceuticals LLCRytary$92$14,92514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →